TRexBio priced an IPO to raise $117 million, adding momentum to a biotech window focused on immune-cell platforms. The company’s offering centers on Tregs, with the pricing highlighting continued investor appetite for cell-based approaches positioned to scale faster and closer to clinical-grade manufacturing.